timothy sykes logo

Stock News

Unexpected Surge: Where Is Geron Headed Next?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Unexpected Surge: Where Is Geron Headed Next? Thumbnail

Geron Corporation stocks have been trading up by 10.45 percent after FDA nod and positive trial results spark investor optimism.

Current Developments

  • Geron Corporation recently announced positive financial results for the first quarter of 2025, reporting $39.4 million in net revenue from its product RYTELO. The company has also received marketing approval in the EU and has significantly progressed its Phase 3 IMpactMF trial, now 85% enrolled.

  • Geron has issued equity awards as an inducement to six new employees, including a package covering 411,000 shares of common stock through stock options and restricted stock units.

  • Analysts at Wedbush have adjusted the target stock price for Geron from $7 to $6, while keeping an Outperform rating. The adjustment results from challenges related to Rytelo’s market uptake, though these are considered manageable.

Candlestick Chart

Live Update At 17:03:12 EST: On Thursday, May 22, 2025 Geron Corporation stock [NASDAQ: GERN] is trending up by 10.45%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Performance Overview

As traders navigate the volatile world of the stock market, making strategic decisions is crucial to avoid unnecessary losses. Adopting a pragmatic and disciplined approach, including managing risks efficiently, can make a significant difference in outcomes. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This quote emphasizes the importance of prioritizing the preservation of capital over potentially risky trades with uncertain returns. Traders should focus on strategies that prioritize risk management to maintain financial stability in the long run.

Geron Corporation is experiencing a period of significant financial evolution. From its latest earnings report, the company delivered $39.4 million in revenue during the latest quarter, predominantly attributed to RYTELO, its breakthrough therapeutic. This product has swiftly gained traction, notably in the EU following its marketing approval. In terms of its operational financials, recent stock price improvements reflect well on the company’s strategic flairs.

A deeper dive into Geron’s financial figures illustrates a dynamic landscape. With total revenues standing at around $39.6 million and gross profits matching the operational revenue, there is discernible optimism around Geron’s potential future profitability — if they continue managing costs aggressively. However, the operating expenses remain stubbornly high, particularly general and administrative expenses clocking in at over $40 million.

Against this backdrop, it’s crucial to note that the company is still grappling with losses. Major key ratios highlight this ongoing struggle, showing negative profit margins and return figures, hinting at substantial room for improvement. Geron’s profitability remains under pressure, yet their cash position is reasonably strong, lending flexibility and potential breathing room for future investments or strategic moves.

More Breaking News

Critical and worth pondering over, Geron’s assets turnover is currently weak, stirring concerns over efficiency. While high current and quick ratios reassure for short-term solvency, the long-term picture remains clouded by high leverage and debt ratios.

Recent Developments and Implications

Geron’s outlook is a mosaic of opportunities balanced by looming challenges. Let’s not forget, it has managed to advance its Phase 3 IMpactMF trial, an endeavor that could wield substantial value. Few companies reach such trial stages without clear focus and drive; Geron is on a sprint, not a marathon here.

Considering additional equity issuance, these moves can dilute shares, but they are instrumental in acquiring talent as the company expands its competitive strength. From a market perspective, there’s cautious optimism. The Wedbush adjustment highlights areas of concern but keeps faith in the larger narrative of innovation Geron is crafting with Rytelo.

What Stockholders Can Expect

If we draw lessons from recent history, Geron’s climb up the stock price ladder may not be meteoric but looks far from an abyssal fall. The company shows promise but bears immense operational costs. Mindful investment in Geron is potentially rewarding yet tactically challenging due to market volatility tied to biotech narratives.

Investors considering allocating or adjusting positions in Geron heed the need for a long-line perspective; a quarter-iconjective approach won’t suffice. As the company edges closer to conclusive results in their trials, spikes in the stock price may accompany favorable news, entailing smart timing and positioning strategies.

Conclusion

In summary, Geron’s recent actions hint at strategic momentum, further buoyed by positive trial progress and EU market penetration. That said, financial metrics hold onto their ever-critical truth, reflecting continuing struggles with profitability and efficiency. Traders should ponder both short-term gains from speculative fervor and long-play, optimism-laden growth driven by eventual clinical and market success. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” As Geron strides forward, its path may be marred by short-term skirmishes, but many will watch, deciding if the tale being spun will yield gold or dawdle in ambitious reverie.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”